- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 21, 2023
Highlights
- Market Cap
- $746.77K
- Enterprise Value
- -$284.98K
- EPS (TTM)
- -$88.55
- Total Revenue (TTM)
- $1.27M
- Gross Profit (TTM)
- $161.30K
- EBITDA (TTM)
- -$9.03M
- Year Range
- $1.62 - $309.89
- ROA (TTM)
- -42.66%
- ROE (TTM)
- -88.10%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ELAB Performance Chart
Elevai Labs Inc. (ELAB) is down 95.3% since the beginning of the year. At $2 per share, ELAB is trading 99.5% below its 52-week high of $310.
Loading charts...
Returns By Period
Elevai Labs Inc. (ELAB) has returned -95.27% so far this year and -99.07% over the past 12 months.
Elevai Labs Inc.
- 1D
- -5.08%
- 1M
- -27.90%
- YTD
- -95.27%
- 6M
- -98.63%
- 1Y
- -99.07%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
ELAB Monthly Returns History
Based on dividend-adjusted daily data since Nov 21, 2023, ELAB's average daily return is -1.22%, while the average monthly return is -26.11%.
Historically, 16% of months were positive and 84% were negative. The best month was Oct 2025 with a return of +12.0%, while the worst month was Nov 2024 at -82.6%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ELAB closed higher 39% of trading days. The best single day was Apr 1, 2026 with a return of +133.7%, while the worst single day was Sep 23, 2024 at -62.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -40.71% | -66.10% | -16.11% | -58.93% | -28.05% | -5.08% | -95.27% | ||||||
| 2025 | -25.33% | -27.19% | -46.87% | -50.54% | -8.73% | 3.35% | -3.24% | -22.49% | -6.94% | 12.00% | -10.38% | -72.13% | -97.37% |
| 2024 | -62.20% | 0.87% | -0.29% | 0.82% | -5.81% | -12.12% | -19.53% | -42.92% | -68.84% | -28.92% | -82.63% | 11.71% | -99.37% |
| 2023 | -17.35% | -34.94% | -46.23% |
Benchmark Metrics
Elevai Labs Inc. has an annualized alpha of -96.95%, beta of 1.80, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 22, 2023.
- This stock participated in 391.44% of S&P 500 Index downside but only -209.78% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -96.95%
- Beta
- 1.80
- R²
- 0.02
- Upside Capture
- -209.78%
- Downside Capture
- 391.44%
Return for Risk
Risk / Return Rank
ELAB ranks 8 for risk / return — in the bottom 8% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Elevai Labs Inc. (ELAB) and compare them to S&P 500 Index.
| ELAB | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.39 | 2.39 | -2.78 |
Sortino ratioReturn per unit of downside risk | -1.60 | 3.25 | -4.85 |
Omega ratioGain probability vs. loss probability | 0.80 | 1.43 | -0.64 |
Calmar ratioReturn relative to maximum drawdown | -1.00 | 3.11 | -4.11 |
Martin ratioReturn relative to average drawdown | -1.44 | 14.38 | -15.82 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Elevai Labs Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Elevai Labs Inc. was 100.00%, occurring on May 21, 2026. The portfolio has not yet recovered.
The current Elevai Labs Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%May 2026 | 2y 5mo | — | 2y 6moNov 2023 - now |
Drawdown Indicators
| ELAB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -99.25% | -9.10% | -90.15% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | 0.00% | -100.00% |
Average DrawdownAverage peak-to-trough decline | -92.77% | -10.72% | -82.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 68.64% | 1.97% | +66.67% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Elevai Labs Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Elevai Labs Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ELAB relative to other companies in the Biotechnology industry. Currently, ELAB has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ELAB in comparison with other companies in the Biotechnology industry. Currently, ELAB has a P/B value of 0.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ELAB
Add Elevai Labs Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ELAB